PL3294279T3 - Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii - Google Patents
Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapiiInfo
- Publication number
- PL3294279T3 PL3294279T3 PL16726183T PL16726183T PL3294279T3 PL 3294279 T3 PL3294279 T3 PL 3294279T3 PL 16726183 T PL16726183 T PL 16726183T PL 16726183 T PL16726183 T PL 16726183T PL 3294279 T3 PL3294279 T3 PL 3294279T3
- Authority
- PL
- Poland
- Prior art keywords
- mucositides
- chemotherapy
- compositions
- treatment
- amino acids
- Prior art date
Links
- 201000010927 Mucositis Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB20150354 | 2015-05-14 | ||
| PCT/IB2016/052724 WO2016181335A1 (en) | 2015-05-14 | 2016-05-12 | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy |
| EP16726183.3A EP3294279B1 (en) | 2015-05-14 | 2016-05-12 | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3294279T3 true PL3294279T3 (pl) | 2020-06-29 |
Family
ID=53765405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16726183T PL3294279T3 (pl) | 2015-05-14 | 2016-05-12 | Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11234949B2 (pl) |
| EP (1) | EP3294279B1 (pl) |
| JP (1) | JP6773269B2 (pl) |
| KR (1) | KR102553890B1 (pl) |
| CN (1) | CN107635554B (pl) |
| BR (1) | BR112017022506A2 (pl) |
| CA (1) | CA2981757C (pl) |
| ES (1) | ES2779749T3 (pl) |
| MY (1) | MY187022A (pl) |
| PL (1) | PL3294279T3 (pl) |
| WO (1) | WO2016181335A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2779749T3 (es) | 2015-05-14 | 2020-08-19 | Professional Dietetics Int Srl | Composiciones que comprenden aminoácidos para uso en el tratamiento de mucositis en pacientes con neoplasia que están sometidos a radioterapia y/o quimioterapia |
| IT201700087376A1 (it) | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| IT201700087359A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
| RU2671512C1 (ru) * | 2018-04-18 | 2018-11-01 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Средство для лечения заболеваний пародонта и слизистой оболочки рта с репаративным эффектом |
| IT201800006725A1 (it) | 2018-06-27 | 2019-12-27 | Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche | |
| IT202000000442A1 (it) * | 2020-01-13 | 2021-07-13 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5438075A (en) | 1993-03-30 | 1995-08-01 | Skubitz; Keith M. | Oral glutamine to reduce stomatitis |
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| MXPA03004546A (es) | 2000-11-22 | 2003-09-10 | Rxkinetix Inc | Tratamiento de mucositis. |
| MXPA05003732A (es) * | 2002-10-08 | 2005-09-30 | Abbott Lab | Metodos y composiciones para proporcionar glutamina. |
| JP2007522077A (ja) | 2003-08-21 | 2007-08-09 | アクセス ファーマシューティカルズ， インコーポレイテッド | 粘膜の疾患および障害の予防および処置のための液体製剤 |
| WO2005039318A1 (en) | 2003-10-16 | 2005-05-06 | Nestec S.A. | Nutritional composition against side effects of chemotherapy of radiotherapy |
| RU2420209C2 (ru) | 2006-10-19 | 2011-06-10 | Нестек С.А. | Долговременное питание для больного раком |
| IT1396935B1 (it) * | 2009-11-26 | 2012-12-20 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici |
| EP2676664B1 (en) | 2011-02-17 | 2017-06-21 | EA Pharma Co., Ltd. | Potentiator of antitumor activity of chemotherapeutic agent |
| SG193928A1 (en) * | 2011-04-12 | 2013-11-29 | Nestec Sa | Nutritional compositions including branched chain fatty acids for improving gut barrier function |
| EP3360428B1 (en) * | 2011-12-15 | 2021-08-04 | Société des Produits Nestlé S.A. | Cohesive thin liquids to promote safe swallowing in dysphagic patients |
| WO2014061808A1 (ja) | 2012-10-19 | 2014-04-24 | 味の素株式会社 | 胃ろう栄養患者用栄養組成物 |
| CN103330215A (zh) * | 2013-07-11 | 2013-10-02 | 西安力邦临床营养有限公司 | 一种适用于肿瘤患者的营养配方食品 |
| KR102265488B1 (ko) | 2013-07-31 | 2021-06-17 | 아지노모토 가부시키가이샤 | 암 화학 요법시의 부작용 경감제 |
| NO3006027T3 (pl) * | 2014-10-08 | 2018-04-14 | ||
| ES2779749T3 (es) | 2015-05-14 | 2020-08-19 | Professional Dietetics Int Srl | Composiciones que comprenden aminoácidos para uso en el tratamiento de mucositis en pacientes con neoplasia que están sometidos a radioterapia y/o quimioterapia |
-
2016
- 2016-05-12 ES ES16726183T patent/ES2779749T3/es active Active
- 2016-05-12 KR KR1020177035602A patent/KR102553890B1/ko active Active
- 2016-05-12 WO PCT/IB2016/052724 patent/WO2016181335A1/en not_active Ceased
- 2016-05-12 CN CN201680026570.5A patent/CN107635554B/zh active Active
- 2016-05-12 JP JP2017552437A patent/JP6773269B2/ja active Active
- 2016-05-12 CA CA2981757A patent/CA2981757C/en active Active
- 2016-05-12 EP EP16726183.3A patent/EP3294279B1/en not_active Revoked
- 2016-05-12 US US15/571,130 patent/US11234949B2/en active Active
- 2016-05-12 MY MYPI2017001528A patent/MY187022A/en unknown
- 2016-05-12 BR BR112017022506-9A patent/BR112017022506A2/pt not_active Application Discontinuation
- 2016-05-12 PL PL16726183T patent/PL3294279T3/pl unknown
-
2021
- 2021-10-29 US US17/515,155 patent/US11896569B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180169042A1 (en) | 2018-06-21 |
| MY187022A (en) | 2021-08-26 |
| ES2779749T3 (es) | 2020-08-19 |
| US11896569B2 (en) | 2024-02-13 |
| CN107635554B (zh) | 2020-11-24 |
| EP3294279B1 (en) | 2020-01-01 |
| CA2981757C (en) | 2023-06-27 |
| US20220047539A1 (en) | 2022-02-17 |
| EP3294279A1 (en) | 2018-03-21 |
| JP6773269B2 (ja) | 2020-10-21 |
| BR112017022506A2 (pt) | 2018-07-17 |
| KR20180004799A (ko) | 2018-01-12 |
| JP2018515441A (ja) | 2018-06-14 |
| US11234949B2 (en) | 2022-02-01 |
| CN107635554A (zh) | 2018-01-26 |
| WO2016181335A1 (en) | 2016-11-17 |
| KR102553890B1 (ko) | 2023-07-12 |
| CA2981757A1 (en) | 2016-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258854A (en) | Preparations containing cannabidiol and secondary medicinal agents for cancer treatment | |
| SG11201912103TA (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| IL266623A (en) | A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer | |
| PL3294279T3 (pl) | Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii | |
| ZA201902873B (en) | Nutritional composition for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL273470A (en) | Semaglutide in medical treatment | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
| IL254228A0 (en) | Cell therapy agent for cancer treatment and combined therapy with it | |
| SG11201610947UA (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| SG11201912098SA (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
| SMT202200151T1 (it) | Composizioni e metodi per l’uso nel trattamento di omocistinuria. | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| PL3402468T3 (pl) | Inhibitory pi3k p-delta 110 do zastosowania w dostarczaniu wirusów w leczeniu nowotworu | |
| IL255169A0 (en) | Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| ZA201902951B (en) | Nutritional composition for use in therapy of cancer patients | |
| PL3325478T3 (pl) | Nowy związek terapeutyczny i zastosowanie w terapii | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| IL255168A0 (en) | Treatment combination of an anti-pogatactic factor and an anti-cancer factor and compounds for the treatment of cancer | |
| SG11201802955VA (en) | Peptides of use in the preventive and curative treatment of alopecia |